After nixing a twice-daily version of its oral GLP-1 agonist, Pfizer is hoping to break into the weight-loss space with a once-daily version, but experts question its outlook.
Tag Archive for: danuglipron
The company made the announcement based on results from the ongoing pharmacokinetic study (NCT06153758), selecting its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans to conduct dose optimization studies in the second half of 2024 evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies.
Although Pfizer has a once-daily version of the weight-loss pill in the works, the decision still marks a blow to its ambition of entering a booming market that analysts expect to be worth $100 billion by the end of the decade.
The company will now focus on its other therapy danuglipron, which Pfizer said last month helped patients lose weight on par with Novo Nordisk’s Ozempic in a mid-stage study that tested it in patients with Type 2 diabetes.